The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2- negative (HER2-) metastatic breast cancer (MBC).

Authors

Sudpreeda Chainitikun

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Sudpreeda Chainitikun , James Long , Ruben Rodriguez-Bautista , Toshiaki Iwase , Debu Tripathy , Takeo Fujii , Naoto T. Ueno

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

First-line systemic treatment with palbociclib in women aged ≥70 years presenting with hormone receptor-positive advanced breast cancer: Results from the PALOMAGE program.

First Author: Elisabeth Carola

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.

First Author: Elgene Lim

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer.

First Author: Hope S. Rugo

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A phase II, single-arm, non-randomized study of alpelisib (BYL719) in combination with continued endocrine therapy following progression on endocrine therapy in hormone receptor–positive, HER2-negative, PIK3CA-mutant metastatic breast cancer: A Big Ten Cancer Research Consortium Study (btcrc-BRE19-409).

First Author: Cristina I. Truica